Search

Your search keyword '"Farina F"' showing total 149 results

Search Constraints

Start Over You searched for: Author "Farina F" Remove constraint Author: "Farina F" Publication Type Electronic Resources Remove constraint Publication Type: Electronic Resources
149 results on '"Farina F"'

Search Results

1. The Corno Alto complex (Adamello batholith): A modern analogue of the high Ba/K sanukitoids

2. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

3. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

4. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

5. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.

6. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

7. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

8. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

9. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

10. A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation

11. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

12. Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience

13. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

14. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

15. Systemic exposure to air pollution induces oxidative stress and inflammation in mouse brain, contributing to neurodegeneration onset

16. Systemic exposure to air pollution induces oxidative stress and inflammation in mouse brain, contributing to neurodegeneration onset

17. LSEA Evaluation of Lipid Mediators of Inflammation in Lung and Cortex of Mice Exposed to Diesel Air Pollution

18. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

19. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

20. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

21. High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study

22. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

23. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

24. Rectangular core-collapse supernova remnants: application to Puppis A

25. LSEA Evaluation of Lipid Mediators of Inflammation in Lung and Cortex of Mice Exposed to Diesel Air Pollution

26. On the collective choice among models of social protection: An experimental study

27. HepaDisk – A new quality of life questionnaire for HCV patients

28. Physiological parameters for Prognosis in Abdominal Sepsis (PIPAS) Study: A WSES observational study

29. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

30. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

31. Clara Sereni. Sconfinamenti e ritorni

32. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study

33. Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper

34. Do high MICs predict the outcome in invasive fusariosis?

35. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study

36. In vivo comparative study on acute and sub-acute biological e_ects induced by ultrafine particles of different anthropogenic sources in balb/c mice

37. In vivo comparative study on acute and sub-acute biological e_ects induced by ultrafine particles of different anthropogenic sources in balb/c mice

38. Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases

39. Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer

40. Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer

41. Ischemic Conditions Affect Rerouting of Tau Protein Levels: Evidences for Alteration in Tau Processing and Secretion in Hippocampal Neurons

42. In healthy normotensive subjects age and blood pressure better predict subclinical vascular and cardiac organ damage than atherosclerosis biomarkers

44. Effects induced by particles derived from two anthropogenic sources on respiratory, cardiovascular and central nervous systems

45. Oxidative stress and inflammation induced by acute and subacute ultrafine exposure: contrinbution to alzheimer's disease

46. Measurement of the muon stopping power in lead tungstate

47. Effects of oxidative stress and inflammation induced by ultrafine particles on Alzheimer disease onset

48. Effects of oxidative stress and inflammation induced by ultrafine particles on Alzheimer disease onset

49. Acute in vivo treatment with ultrafine particles form two different anthropogenic sources

50. ALK inhibitors for clinical use in cancer therapy

Catalog

Books, media, physical & digital resources